Overview of Enrotab

Quick Facts

Property	Description
Active ingredient	Enrofloxacin
Form	Tablets (Solid oral preparation)
Pharmacological class	Fluoroquinolone Antibiotic
Intended Use Domain	Veterinary Medicine
Origin	Synthetic Compound

What is Enrotab? Identity and Classification

Enrotab is the commercial designation for a pharmaceutical preparation intended exclusively for veterinary medicine, where its active ingredient is the powerful synthetic compound known as Enrofloxacin. This substance is formally classified as an antibiotic belonging to the fluoroquinolone class, a specialized group of antimicrobial agents.

The drug is chemically synthesized, distinguishing it from antibiotics derived from natural sources, and is clinically recognized for its high efficacy against a wide range of bacterial pathogens in veterinary patients. The core function of Enrotab is to serve as a targeted, broad-spectrum agent to combat infectious diseases, a crucial tool in modern veterinary care.

Enrofloxacin: Composition and Delivery Form

The product's efficacy is derived from Enrofloxacin, the single active ingredient comprising the therapeutic core of Enrotab. This preparation is formulated as tablets, a solid dosage form intended for oral administration. The tablet structure consists of the therapeutic substance alongside solid excipients (binders, diluents, and coatings), which are materials necessary for creating a stable, measured dose unit. This controlled solid form ensures that a precise and consistent amount of the active ingredient is delivered for predictable absorption into the bloodstream.

General Therapeutic Purpose of the Fluoroquinolone Class

The fundamental purpose of this class of medicine is to eliminate harmful microbial populations through a definitive bactericidal action, which is necessary for resolving an infection. Enrofloxacin achieves this by targeting the vital process of nucleic acid synthesis within susceptible bacteria. Specifically, it interferes with two critical bacterial enzymes, DNA gyrase and topoisomerase IV, thereby preventing the pathogens from multiplying. This mechanism provides the benefit of effective broad-spectrum activity designed to rapidly clear the microbial burden responsible for the infectious state, such as in cases of severe systemic infections in companion animals.

What side effects are possible with Enrotab?

Possible side effects and safety information

The safety profile of Enrotab, which contains the fluoroquinolone antibiotic Enrofloxacin, is strictly defined by government regulatory documents based on the affected physiological system and frequency of occurrence.

Documented Adverse Reactions and Frequencies

Adverse reactions are classified into categories according to official regulatory standards. Gastrointestinal Disorders are the most common adverse reactions reported, and may include vomiting, diarrhea, and anorexia (loss of appetite).

Reactions categorized as rare or very rare involve other systems. These include Nervous System Disorders such as ataxia and seizures.

Serious Adverse Reactions and Population-Specific Safety

Regulatory labeling highlights specific serious safety concerns that constrain the use of Enrotab in certain populations.

Musculoskeletal and Connective Tissue Disorders: The medicine is officially contraindicated for use in young, rapidly growing dogs (typically under 12 to 18 months, depending on breed) due to the documented risk of severe, irreversible Articular Cartilage Defects.
Eye Disorders: A specific, dose-dependent risk of Retinal Damage (leading to acute blindness) is documented for Feline species (cats). This necessitates a strict maximum dose limitation for this species.

General Safety Constraints

The product is contraindicated in any animal with known hypersensitivity to the fluoroquinolone class. A high-level safety note in regulatory text also addresses the potential for interaction with drugs metabolized by the Cytochrome P450 system, which may affect clearance and heighten the risk of adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Enrotab (Enrofloxacin) is officially documented to result in acute systemic effects and critical, species-specific risks, necessitating immediate emergency action. The documented effects are based strictly on regulatory labeling and drug monographs.

Documented Overdose Manifestations

Regulatory information describes overdose presentations primarily affecting two systems. Gastrointestinal signs include vomiting, diarrhoea, and anorexia (lack of appetite). Neurological signs are characterized by central nervous system (CNS) disturbances, such as excitation, tremors, ataxia (loss of coordination), and the potential for convulsive seizures. This risk of CNS stimulation is specifically noted for animals with pre-existing CNS disorders.

Severe Outcomes and Emergency Action

A key officially documented outcome is the risk of irreversible ocular damage and blindness in cats when the recommended dose is significantly exceeded. Due to the severity of potential manifestations, immediate contact with a veterinarian or animal poison control center is required if an overdose is suspected. Regulatory documents explicitly state that no specific antidote is known for Enrofloxacin toxicity. Management is therefore limited to providing symptomatic and supportive treatment to address the observed clinical signs.

Therapeutic Uses of Enrotab

Enrotab is an option for supportive care in managing various bacterial infections in dogs and cats, focusing on acute and chronic clinical scenarios where susceptible organisms are present.

The medicine may assist in the therapeutic management of infections affecting the urinary tract (such as cystitis and pyelonephritis), dermatological issues (like superficial and deep pyoderma), and upper respiratory tract infections in cats. For these conditions, the principal benefit is often symptom management and resolving the underlying infection.

Quick Fact: Relief for Skin Inflammation

Enrotab can contribute to the resolution of bacterial skin infections, often leading to a reduction in associated discomfort and redness for the animal.

Eligibility and Restrictions for Use

The eligibility to use Enrotab is strictly determined by regulatory documents, which specify clear population restrictions for this veterinary fluoroquinolone antibiotic.

Use is contraindicated (must not be used) in animals with documented hypersensitivity to enrofloxacin or other fluoroquinolones, and in animals with known microbial resistance to the drug class. The medicine is also contraindicated in dogs diagnosed with seizure disorders.

Specific age-related eligibility rules strictly prohibit the drug in young, growing animals: dogs must not use Enrotab during their rapid growth phase (which extends up to 18 months for large breeds), and cats must be older than 8 weeks of age. These limitations protect developing articular cartilage.

Restricted Use/Caution	Limitation Basis
Pregnant/Lactating Animals	Use is not recommended as safety has not been officially established.
Severe Impairment	Caution is required for animals with severe hepatic or renal impairment.
Cats	Species-specific limitations are imposed to prevent exceeding the dose associated with ocular toxicity (risk of blindness).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Enrotab (Enrofloxacin) includes constraints related to co-administration with other medicinal products and certain substances, primarily due to effects on absorption or elimination pathways.

Interaction Type	Interacting Agent(s)	Regulatory Finding	Classification
Antimicrobial Conflict	Macrolides, Tetracyclines, Phenicols	Potential for antagonistic effects	Contraindicated
Reduced Absorption	Antacids (containing Aluminium/Magnesium), Supplements (Iron, Zinc, Calcium)	Binds Enrofloxacin, which impairs absorption and lowers serum levels	Significant Interaction
Altered Clearance	Theophylline	Concurrent use may result in the delayed elimination of Theophylline	Caution Required
Pharmacokinetic Effect	Digoxin	May potentially increase the oral bioavailability of Digoxin	Caution Required

Co-administration of the specified mineral-containing substances, including certain dairy products, requires a separation of administration to prevent interference with intestinal absorption. Sucralfate also requires a time separation of at least two hours. Furthermore, regulatory documents advise that the product should be used with caution in animals with severe renal or hepatic impairment because the drug's elimination may be delayed in these specific populations. Concomitant use with oral anticoagulants may increase their action.

Mechanism of Action

Selective Inhibition of Bacterial DNA Gyrase and Topoisomerase IV

Enrotab's action begins at the molecular level by selectively inhibiting two bacterial enzymes: DNA Gyrase and Topoisomerase IV. These two enzymes are essential for maintaining the topological structure of the bacterial chromosome, a process entirely distinct from the corresponding enzymes in the animal host.

The Lethal Cascade of DNA Fragmentation

By binding to and stabilizing the cleaved DNA-enzyme intermediate, Enrofloxacin prevents the re-ligation of severed DNA strands, causing a buildup of double-strand breaks and physical obstruction. This cascade rapidly disrupts the bacterial DNA replication and transcription pathways, leading directly to concentration-dependent cell death (bactericidal effect) and the consequent elimination of the active bacterial population.

️ Constraints on Mechanistic Efficacy

The functional capacity of this mechanism is constrained by bacterial resistance strategies, primarily involving target-site mutations that reduce the drug's binding affinity to the enzymes, and the over-activation of efflux pumps that actively expel Enrofloxacin from the bacterial cell.

Dosage and Administration Information

How to Use Enrotab: Official Administration Guidelines

This section describes the high-level, standardized usage of Enrotab (Enrofloxacin tablets).

Administration Scope

Parameter	Official Instruction (Label-Based)
Route of administration	The medicine is strictly for oral use only, as it is formulated as a solid oral tablet.
Dosing schedule	Dogs: Administered at a rate providing 5 to 20 mg/kg of body weight daily. Cats: The standard dose is 5 mg/kg of body weight daily.
Frequency and timing	The total daily dose may be given as a single administration (q24h) or, alternatively, it can be divided into two equal doses and given 12 hours apart (q12h).
Timing in relation to meals	Administration may be performed with or without food. However, absorption of the active ingredient may be enhanced when given on an empty stomach.

Usage Constraints and Duration

Parameter	Official Constraint
Special procedural conditions	Concurrent oral administration must be avoided with substances containing calcium, iron, or aluminum (such as antacids or supplements), as these compounds can reduce drug absorption.
Course duration	Treatment should continue for at least 2 to 3 days beyond the cessation of clinical signs. The total duration of administration is restricted and must not exceed 30 days.
Population consideration	High-level care and dose monitoring are advised for patients with diagnosed severe renal or hepatic impairment.

Procedural Summary

The usage protocol requires precise calculation of the milligram-per-kilogram dose based on the patient's weight and species, which must then be administered orally according to the approved daily or divided schedule. Tablets are typically scored to allow for accurate dose division. Adherence to the minimum and maximum duration limits is mandated to complete the full course.

Recent Clinical Evidence

Research evidence / Overview of Studies for Enrotab (Enrofloxacin)

Evidence for Use in Dermal Infections (Skin and Wound Issues)

Research into Enrotab for bacterial skin infections has primarily involved Clinical Field Trials. These studies were evaluated in dogs and cats with conditions associated with acute or disruptive episodes, such as infected wounds or abscesses caused by bacteria known to be susceptible to this medicine. This section will summarize the type of clinical field trials and microbiological studies that describe studies that evaluated Enrotab for bacterial infections of the skin, including the primary outcomes researchers measured, such as wound healing and bacterial clearance.

The studies examined the time it took for the signs of infection to subside and whether the targeted bacteria were completely cleared. Findings describe patterns observed in the studies, reporting how the resolution of clinical signs was measured in animals given the medicine. It is important to note that many of the initial pivotal trials supporting approval are Clinical Field Trials and may not have been fully randomized or blinded like some human drug trials. As such, the evidence is heterogeneous across studies. Additionally, there is limited information for long-term outcomes that look at whether the infection returns months later.

Evidence for Use in Respiratory Infections

Research exploring the use of Enrotab for respiratory infections was evaluated in dogs and cats with conditions involving periods of heightened symptoms, such as severe coughing or discharge. The studies monitored clinical success, focusing on outcomes reflecting daily functioning or activity level and the measurement of systemic or functional imbalance related to the infection. Specialized Pharmacokinetic (PK) studies were also conducted to understand the drug's concentration in the lungs and other tissues.

The results report how symptoms evolved in the observed populations during the study period. Evidence from PK studies describes the concentration of the medicine achieved in the respiratory tract and relates it to the minimum concentrations required to inhibit target bacteria. The evidence for this indication is heterogeneous (variability) across the various studies conducted, including different disease types and animal populations. Furthermore, the follow-up durations were limited, typically assessing outcomes only for the short period immediately following treatment, meaning the long-term effects are not fully established regarding recurrence or chronic management.

What is Still Uncertain About the Research for Enrotab

There are several areas where the evidence is limited or where research is ongoing. A significant concern noted in the scientific literature is the potential for antimicrobial resistance, which means research is exploring how the observed patterns may change over time as bacteria adapt. The evidence is heterogeneous across studies, and many core regulatory studies were not large-scale, blinded, randomized trials, which contributes to the overall uncertainty. The research highlights what is known—and what is still uncertain—about group patterns, but research does not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Enrotab (FAQ)

Q: Is Enrotab available over the counter, or is it prescription only?

Regulatory classification documents state that Enrotab is a Prescription Only Medicine (POM) intended for veterinary use. Its classification indicates that it is only available via prescription and is not available for purchase over the counter.

Q: Is Enrotab in the same drug class as another medicine I might be familiar with?

The official classification of Enrotab is a fluoroquinolone antibiotic. This drug class includes other antimicrobial agents that are used for various infectious diseases in both human and veterinary medicine.

Q: Is Enrotab primarily used for short-term illnesses or for chronic, ongoing conditions?

According to the official instructions, the total duration of administration is restricted and is described as generally not exceeding 30 days, indicating its use is for acute or sub-acute infectious episodes.

Q: How long does Enrotab typically stay in your system?

Pharmacokinetic studies summarized in official documents report that the elimination half-life of the active ingredient typically ranges between 3 to 7 hours in the target species. The half-life describes the time it takes for the amount of drug in the body to be reduced by half.

Q: What is the expected time frame for Enrotab to start showing an effect?

Although a specific clinical onset time is not listed, the medicine’s mechanism is described as having rapid bactericidal action. Official information indicates that resolution of clinical signs is commonly measured after 2 to 3 days of treatment.

Q: Is Enrotab categorized as a long-acting or a short-acting medicine?

The approved dosing schedule allows for the total daily dose to be given either once a day (q24h) or divided into two doses (q12h). This regimen indicates that the active ingredient’s effect is sustained over a period of up to 24 hours.

Q: Does Enrotab carry any official risk of addiction or dependence?

Regulatory documents listing the safety profile and adverse reactions do not include addiction or dependence as an associated risk or reported adverse reaction for the active ingredient.

Q: Is it normal to feel slightly unwell when first starting a course of Enrotab?

Official product information notes that Gastrointestinal Disorders (including vomiting and loss of appetite) are the most common adverse reactions reported. These effects may occur when first starting a course of the medicine.

Q: Do clinical trials of Enrotab indicate that it is generally well-tolerated?

Clinical trials describe the drug’s safety profile but note that evidence can be heterogeneous across studies. The trials report that the most common adverse reactions are Gastrointestinal Disorders.

Q: Can Enrotab make you feel dizzy or lightheaded?

Official documents on adverse reactions list nervous system disorders like ataxia (lack of coordination) and seizures. However, the specific symptoms of dizziness or lightheadedness are not explicitly listed in the reported reactions found in regulatory documents.

Q: Why do some users online report that Enrotab caused them increased tiredness?

Official regulatory documents detailing the side effect profile do not list tiredness, fatigue, or lethargy as reported adverse reactions. Official information is limited to the side effects described in the formal product documents.

Q: Does Enrotab officially cause changes in sleep patterns or insomnia?

Official side effects list nervous system disorders (ataxia, seizures) but do not list changes in sleep patterns or insomnia as reported adverse reactions.

Q: Are headaches a commonly listed side effect of Enrotab?

Official documents list nervous system disorders (ataxia, seizures) but do not list headaches as a reported adverse reaction for the medicine.

Q: Does Enrotab cause issues with blood pressure or heart rate?

Regulatory documents listing adverse reactions do not include adverse cardiovascular events such as changes in blood pressure or heart rate as reported side effects.

Q: Is Enrotab appropriate for people with known heart conditions or existing heart disease?

Regulatory documents detailing contraindications and warnings do not list known heart conditions or existing heart disease as a required caution or prohibition for use.

Q: Does Enrotab interact with common herbal supplements like St. John's Wort?

Regulatory documents include a Caution related to the use of the medicine with other drugs that are metabolized by the Cytochrome P450 system. While specific herbal supplements like St. John’s Wort are not explicitly named, this warning applies generally to agents that affect this pathway.

Q: Can I use a regular pain reliever like acetaminophen or ibuprofen with Enrotab?

Regulatory documents list interactions with drugs metabolized by the Cytochrome P450 system, but they do not explicitly name common pain relievers like Acetaminophen or Ibuprofen in the official interaction warnings.

Q: What is the recommended time window for taking a forgotten dose of Enrotab?

Guidance for missed doses often refers to administration as soon as remembered, unless the next scheduled dose is imminent, in which case the regular schedule is described as continuing.

Q: What should be done if an Enrotab dose is accidentally taken twice?

The regulatory documents describe the management of overdose, noting that this typically involves symptomatic treatment and supportive measures under professional guidance.

Q: Are there different strengths or formulations of Enrotab available from the manufacturer?

The regulatory documents explicitly state the available strengths and pharmaceutical form of the product. The product is formulated as tablets and may be available in multiple strengths, such as 50 mg, 100 mg, and 250 mg.

Q: Where can I find the official regulatory information or prescribing insert for Enrotab?

The regulatory prescribing information is compiled in comprehensive documents such as the DailyMed record or the EMA Public Assessment Report. These detailed documents are indexed and made publicly accessible by government health authorities.

How should Enrotab be stored and disposed of?

How to Store and Dispose of Enrotab? Official Requirements

Official regulatory documents define specific storage and disposal requirements for Enrotab (enrofloxacin) to maintain its stability and ensure environmental safety.

Storage Conditions

Temperature: Store the product below 25 C (77 F). It is explicitly required to not freeze and not refrigerate the tablets.
Protection: The medicine must be protected from light and moisture and should be kept in the original container, which must be tightly closed.
Child Safety: Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Enrotab must be disposed of in accordance with local requirements to an approved waste disposal plant. It is officially restricted to not release the product to the environment, which prohibits disposal via household trash or wastewater.

Enrotab